Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multiple Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

NCT07100119 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07100119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07100119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multiple Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Recruiting
Start date
August 5, 2025
Completion date
September 30, 2027
Enrollment
32 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

als (amyotrophic lateral sclerosis)